Back to Search
Start Over
Cinacalcet: pharmacological and clinical aspects.
- Source :
-
Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2008 Dec; Vol. 4 (12), pp. 1551-60. - Publication Year :
- 2008
-
Abstract
- The calcium sensing receptor (CaSR) is expressed in cells secreting calcium-regulating hormones, in cells involved in calcium transport and in many other tissues, with an as yet not completely defined role. In parathyroid cells, the CaSR stimulation inhibits parathyroid hormone (PTH) secretion, synthesis and parathyroid cell proliferation. Cinacalcet belongs to calcimimetic type II compounds that can interact with CaSR, increasing its affinity for calcium. Clinical studies have proved cinacalcet to be effective in reducing calcium and PTH levels in primary hyperparathyroidism and in reducing PTH, calcium and phosphate in patients with secondary hyperparathyroidism owing to chronic renal failure, with a relatively safe profile, the only reported adverse events being hypocalcaemia and gastrointestinal symptoms. However, though calcimimetics do represent a real advancement in the field of the treatment of PTH secretion disturbances, there is a need for clinical trials, which should aim to demonstrate that a better control of biochemical parameters is also matched with better clinical outcomes.
- Subjects :
- Calcium antagonists & inhibitors
Calcium metabolism
Cinacalcet
Clinical Trials as Topic economics
Clinical Trials as Topic methods
Cost-Benefit Analysis
Humans
Hyperparathyroidism drug therapy
Naphthalenes economics
Parathyroid Hormone antagonists & inhibitors
Parathyroid Hormone metabolism
Receptors, Calcium-Sensing agonists
Treatment Outcome
Naphthalenes pharmacology
Naphthalenes therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1742-5255
- Volume :
- 4
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Expert opinion on drug metabolism & toxicology
- Publication Type :
- Academic Journal
- Accession number :
- 19040330
- Full Text :
- https://doi.org/10.1517/17425250802587017